Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study

benzinga.com/news/health-care/25/10/48098211/sanofi-alphamedix-milestone-study-for-gep-nets

Sanofi SA (NASDAQ:SNY) on Wednesday released topline data from a phase 2 study evaluating the efficacy and safety of AlphaMedix (212Pb-DOTAMTATE).
The patients had unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), positive somatostatin analog imaging,…

This story appeared on benzinga.com, 2025-10-08 13:04:07.
The Entire Business World on a Single Page. Free to Use →